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The Polycomb group (PcG) proteins form chromatin-modifying complexes that are essential for embryonic
development and stem cell renewal and are commonly deregulated in cancer. Here, we identify their target
genes using genome-wide location analysis in human embryonic fibroblasts. We find that
Polycomb-Repressive Complex 1 (PRC1), PRC2, and tri-methylated histone H3K27 co-occupy >1000 silenced
genes with a strong functional bias for embryonic development and cell fate decisions. We functionally
identify 40 genes derepressed in human embryonic fibroblasts depleted of the PRC2 components (EZH2, EED,
SUZ12) and the PRC1 component, BMI-1. Interestingly, several markers of osteogenesis, adipogenesis, and
chrondrogenesis are among these genes, consistent with the mesenchymal origin of fibroblasts. Using a
neuronal model of differentiation, we delineate two different mechanisms for regulating PcG target genes. For
genes activated during differentiation, PcGs are displaced. However, for genes repressed during differentiation,
we paradoxically find that they are already bound by the PcGs in nondifferentiated cells despite being actively
transcribed. Our results are consistent with the hypothesis that PcGs are part of a preprogrammed memory
system established during embryogenesis marking certain key genes for repressive signals during subsequent
developmental and differentiation processes.
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The human body consists of at least 200 different types
of cells. The response of each of these cells to extra- or
intracellular signals depends on their particular lineage
“identity.” In other words, despite having identical ge-
nomes, cells can respond in markedly different ways to
the same stimulus. Therefore, a strong “programming”
system must function to preserve and specify the iden-
tity of each cell type. It has become increasingly clear in
recent years that maintenance of cell identity and, to a
certain extent, also specification of cell identity are con-
trolled by epigenetic events (Fisher 2002; Jaenisch and
Bird 2003; Hsieh and Gage 2004; Valk-Lingbeek et al.
2004). These epigenetic events, which include DNA
methylation and post-translational modifications of the
histones, control the transcriptional program of each cell
by regulating chromatin structure. The histone modifi-
cations are thought to constitute an indexing mecha-
nism, referred to as the “histone code” (Jenuwein and
Allis 2001), containing information such as the past and
present gene activity and the physiological status of the
cell. This code is deciphered by other protein complexes,
which specifically recognize and bind the modified his-
tones and, in turn, elicit the biological effects of the im-
prints. The Polycomb repressors and Trithorax activa-
tors are thought to be the central players in these epige-
netic programming events (Orlando 2003; Molofsky et
al. 2004; Valk-Lingbeek et al. 2004).
Polycomb group genes (PcGs) are usually considered as
being transcriptional repressors that are required for
maintaining the correct spatial and temporal expression
of homeotic genes during development and were origi-
nally identified based on studies demonstrating that de-
letions of PcG genes lead to homeotic transformations of
fruit flies (Orlando 2003; Ringrose and Paro 2004; Pir-
rotta and Gross 2005). The vertebrate homeotic HOX
genes are located in four distinct clusters (A, B, C, D) that
are organized into 13 homology (or paralog) groups (Pear-
son et al. 2005). The chromosomal organization of the
genes in each HOX cluster reflects its anterior–posterior
expression in the body plan. The “tail” HOX genes at the
5 end of the HOXA locus (i.e., HOXA7–13) are ex-
pressed predominantly in the posterior of the developing
embryo. In PcG knockout mice, the repression of these
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“tail” HOX genes is impaired in the middle and head
part of the embryo, resulting in posterior-to-anterior
transformation defects (Levine et al. 2004; Lund and van
Lohuizen 2004).
Recent biochemical approaches have established that
the PcG proteins form multiprotein complexes, called
Polycomb-Repressive Complexes (PRCs). PRC2 contains
EZH2, EED, SUZ12, and RbAp48, while the PRC1 com-
plex consists of >10 subunits including the oncoprotein
BMI-1 and the HPC proteins (CBX2, CBX4, CBX7,
CBX8), HPH1-3, RING1-2, and SCML (Levine et al.
2004; N. Dietrich, K. Helin, and K.H. Hansen, unpubl.).
Functionally, EZH2 is the catalytically active compo-
nent of PRC2, acting as a histone methyltransferase spe-
cific for Lys 27 (K27) of histone H3 and K26 of histone H1
(Cao and Zhang 2004; Kuzmichev et al. 2004). Interest-
ingly, the HPC proteins of the PRC1 complex can spe-
cifically bind to tri-methylated H3K27 (H3K27me3) (Cao
and Zhang 2004; Kuzmichev et al. 2004; N. Dietrich, K.
Helin, and K.H. Hansen, unpubl.). Since PRC2 is re-
quired for PRC1 binding to chromatin (Rastelli et al.
1993; Hernandez-Munoz et al. 2005), it has been pro-
posed that this is primarily achieved through binding of
HPC proteins to H3K27me3. Recently, the PRC1 com-
plex has been demonstrated to possess a H2A-K119 ubiq-
uitin E3 ligase activity that, like H3K27me3 activity, is
associated with the repression of HOX genes (Cao et al.
2005).
In addition to being essential regulators of embryonic
development, the PcGs have also emerged as key players
in the maintenance of the adult stem cell populations
(Molofsky et al. 2004; Valk-Lingbeek et al. 2004). For
example, BMI-1 is required for the self-renewal of hema-
topoietic and neural stem cells (Lessard and Sauvageau
2003; Molofsky et al. 2003), while overexpression of
EZH2 is capable of blocking the differentiation of muscle
myoblasts (Caretti et al. 2004) and preventing hemato-
poietic stem cell exhaustion (Kamminga et al. 2005).
Consistent with their critical roles in development, dif-
ferentiation, and stem cell renewal, several PcGs are on-
cogenes, overexpressed in both solid and hematopoietic
cancers (Pasini et al. 2004a; Valk-Lingbeek et al. 2004;
Raaphorst 2005).
Although substantial progress has been made toward
understanding the biological and biochemical functions
of PcG proteins, we still know little about how precisely
they control development and cell fate decisions. Since it
is believed that they primarily function as epigenetic
regulators of transcription, we performed chromatin im-
munoprecipitations (ChIP) and genome-wide screenings
using tiled arrays to identify PcG target genes in human
cells. Strikingly, we observe a very strong bias for genes
controlling development and cell fate decisions. We in-
vestigate the functional relevance of PcG regulation in
both human embryonic fibroblasts and in a model of
neuronal differentiation. Moreover, we show that the
PcGs target several tumor suppressor genes and genes
known to be down-regulated in cancer. Based on these
data, we propose models for how the PcGs control tran-
scription.
Results
Identification of gene expression changes in cells
depleted of PRC1 and PRC2 members
To obtain an understanding of how the PcGs control
development and cell fate decisions, we chose to identify
their target genes. To do this, we wanted to perform
ChIP experiments using specific PcG antibodies fol-
lowed by probing of microarrays (chips) with the en-
riched material (ChIP-on-chip). As an initial screen, we
identified candidate genes by performing expression ar-
ray analysis of PcG-depleted cells. Then subsequently,
by generating tiled arrays mapping the complete loci of
these potential target genes and probing with the en-
riched material, we aimed to identify functionally rel-
evant direct targets.
We transfected proliferating human embryonic diploid
fibroblasts (TIG3) with small interfering RNA (siRNA)
oligonucleotides specific for the PRC2 components
(EZH2, EED, and SUZ12) or the PRC1 component BMI-1.
Western blot analysis of lysates prepared 44 h after trans-
fection confirmed that the siRNAs efficiently inhibited
the protein synthesis of their specific targets (Fig. 1A). As
described previously, the protein levels of PRC2 mem-
bers are in part dependent on the presence of the other
partners in the complex (Pasini et al. 2004b). RNA was
extracted at this point and labeled and hybridized to Af-
fymetrix gene expression arrays (HG-U133). The short
incubation period with siRNA oligonucleotides gener-
ated small but reproducible expression changes in sev-
eral hundred genes. We observed a substantial overlap in
gene expression changes after inhibiting the expression
of BMI-1 and the three proteins of the PRC2 complex
(Fig. 1B). In order not to miss any relevant genes for the
subsequent ChIP-on-chip analysis, we selected a total of
341 genes as potential PcG target genes, whose expres-
sion is significantly changed upon down-regulation of at
least three out of the four PcG proteins analyzed in our
experiments (Fig. 1C; Supplementary Table 1). The reli-
ability of the expression array data was confirmed by
performing quantitative real-time PCR analysis (qPCR)
of a selection of 18 genes (Fig. 1D; data not shown).
PcG binding and overlapping H3K27 tri-methylation
of complete gene loci in the HOX gene clusters
To identify target genes by ChIP analysis, we first
screened several candidate antibodies specific for PRC1
and PRC2 proteins and the tri-methylated H3K27 for
their ability to efficiently coimmunoprecipitate histone
H3 in ChIP conditions (data not shown). From this analy-
sis we selected antibodies specific for SUZ12 (PRC2),
CBX8 (PRC1), and H3K27me3. To validate the specific-
ity of these antibodies in the ChIP-on-chip analysis, we
represented the entire HOXA, HOXB, HOXC, and
HOXD loci on tiled chips. We probed these chips with
DNA amplified by ligation-mediated PCR from ChIPs
performed with antibodies specific for H3K27me3,
SUZ12, and CBX8 using an antibody for HA as a negative
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control and an antibody for E2F3 as a positive control for
the ChIP technique. In Figure 2, A and B, the enrich-
ments observed across the entire HOXA locus are de-
picted at high resolution in Log2 and normal scale, re-
spectively. Very strong enrichments of SUZ12, CBX8,
and H3K27me3 were observed immediately downstream
of the HOXA9 gene and extend upstream of the
HOXA13 gene, a stretch of ∼45 kb. Interestingly, the
enrichments observed on the HOXA9–13 genes “blan-
ket” their complete gene loci, and are not restricted to
their promoter regions. Similar robust enrichments were
observed on the HOXB, HOXC, and HOXD loci (Supple-
mentary Fig. S1). As a further confirmation of the anti-
body specificity, we did not observe any significant en-
richment of PcGs or H3K27me3 on a large number of
control genes, including the E2F target genes CDC6 and
CCNA2 (Supplementary Fig. S2).
To validate the enrichment profiles observed on the
tiled chips, we quantified the immunoprecipitated DNA
enrichments by qPCR of an independent ChIP experi-
ment using primers designed within the promoter re-
gions of all the HOXA genes (Fig. 2C). This established
that EZH2 binds along the HOXA locus with an almost
identical profile to SUZ12, CBX8, and H3K27me3. Sig-
nificantly, Polymerase II was only detected at the pro-
moters of the HOXA4 and HOXA5 genes, which are the
only paralogs expressed in embryonic fibroblasts, consis-
tent with the fact that these cells are of mesodermal origin.
Identification of target genes whose expression is
regulated by the PcGs
Next, we represented the 341 gene loci of the genes iden-
tified in the expression array analysis starting from 15 kb
upstream of the transcriptional start site (TSS) and end-
ing 5 kb downstream of the 3 end of the last known exon
(Supplementary Table 1) on custom designed tiled chips.
We hybridized these chips with the DNA used for the
analysis of the HOX loci. Specific enrichments of CBX8,
SUZ12, and H3K27me3 were detected either at the pro-
moter or elsewhere within the gene locus of 43 genes,
represented as a treeview plot in Figure 3A. A detailed
description of the exact PcG-binding positions on these
genes is given in Supplementary Table 2. We observed
enrichments of two types, either in confined “bell
curves” that center around a particular point or as the
“blanket” type, possibly consisting of multiple peaks
fused together. For example, SUZ12, H3K27me3, and
CBX8 form bell curve enrichments within the TSS of the
ATF3, BMP2, and DKK2 genes (Fig. 3B; Supplementary
Fig. S3), while blanket-type enrichments are observed on
the OTX2, CCND2, and MT1G genes (Fig. 3B; Supple-
mentary Fig. S3; Supplementary Table 2). The MT1G
gene is part of the metallothionein multigene cluster
(MT1E, MT1J, MT1A, MT1B, MT1F, MT1G, and MT1H),
which has blanket-type enrichments analogous to the
HOX loci (Supplementary Fig. S3; Supplementary Table 3).
Figure 1. Genome-wide expression screen to identify gene changes in Polycomb depleted cells. (A) Western blot analysis of lysates
prepared from TIG3 fibroblasts 44 h after transfection with siRNA oligos designed to inhibit the expression of EZH2, EED, SUZ12, or
BMI-1. Tubulin was used as a loading control. (B) Venn diagram depicting the overlap in genes increased >1.2-fold in PRC2 (EZH2, EED,
and SUZ12 combined) and PRC1 (BMI-1) depletion. (C) Treeview representation of Affymetrix expression data depicting the gene
expression changes in Polycomb-depleted cells. (D) Validation of gene expression changes by qPCR for a selection of genes (indicated
in B). mRNA was prepared from TIG3 cells transfected with Mock (M), EZH2 (Z), EED (E), SUZ12 (S), or BMI-1 (B) siRNAs. The
experiments were performed independently of the gene expression array experiments.
Polycomb target genes
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Intriguingly, SUZ12 and CBX8 are also found on the
BMI-1 and CBX8 gene loci and are associated with
H3K27me3 enrichments (Fig. 3B; Supplementary Fig.
S3). The expression of BMI-1 and CBX8 increases follow-
ing the siRNA-mediated depletion of other PRC1 or
PRC2 members (Figs. 1A, 3A). Therefore, these data sug-
gest that PcG proteins autoregulate their own synthesis.
This is conserved during evolution, since PcG proteins
bind to the polyhomeotic (Ph) locus in Drosophila (Fau-
varque et al. 1995; Bloyer et al. 2003).
Next we validated a selection of these newly identified
target genes, for EZH2, SUZ12, CBX8, and H3K27me3
enrichments in an independent experiment (Fig. 3C).
The previously identified SUZ12 target gene MYT1 (Kir-
mizis et al. 2004) was included as a positive control and
the HOXA1 and CCNA2 genes as negative controls. Fi-
nally, the expression of several target genes (MT1G,
CCND2, SERPINB2, and CYPB1) were tested and shown
to be reduced in BMI-1-overexpressing TIG3 cells (data
not shown), further validating them as PcG target genes
in this cellular system. We conclude that we have iden-
tified 43 target genes of the PcG proteins, whose expres-
sion changes in PcG-depleted cells.
Perhaps surprisingly, the mRNA transcripts of the pre-
viously characterized SUZ12 target gene MYT1 as well
the HOXA7–13 genes remained undetectable in PcG-de-
pleted cells (data not shown). This is despite the fact that
we observe strong PcG enrichments on their promoters
(Figs. 2C, 3C). Therefore, in order to identify all PcG
target genes in human embryonic fibroblasts, we decided
to perform a global unbiased identification of PcG-bound
promoters independent of their expression.
Genome-wide identification of human promoters
bound by PcG
We interrogated chips containing probes for 24,275 hu-
man promoters within a defined region spanning 1300
base pairs (bp) upstream to 200 bp downstream of the
TSS. Significantly, the PcGs bind within this limited
promoter region in 70% of the target genes described in
Figure 3A (see Supplementary Table 2). As shown in Fig-
Figure 2. The PcG proteins and H3K27me3 are highly enriched on the HOXA gene cluster. (A) ChIP-on-chip tiling array analysis of
the HOXA locus spanning 140 kb of DNA starting at position 26,880,000 on chromosome 7. High-resolution mapping of the 140 kb
was achieved by representing 2840 probes of 50 bp with an average spacing of 3 bp between probes. The Y-axis represents the Log2
signal ratios (bound/input) for the indicated antibodies. The results of the promoter ChIP-on-chip experiment are also shown for the
HOXA promoters. In this analysis, chips were used containing 24,275 human promoters from 1300 bp upstream to 200 bp downstream
of TSS with 15 50-bp probes with an average spacing of 100 bp between probes. (C) Custom ChIP-on-chip data; (P) Promoter ChIP-
on-chip data. (B) XY scatterplot representation of the data depicted in A, created by plotting the average enrichments at 5-kb intervals.
(C) Normal ChIP analysis of the promoters of the HOXA gene cluster. Primers were designed within the promoter regions (indicated
with red bars) of all HOXA genes as indicated at the top of the panel. Enrichment is shown as percentage input.
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ure 4A and listed in Supplementary Table 3, SUZ12,
CBX8, and H3K27me3 are present on a very large num-
ber of promoters. A significant enrichment was found for
CBX8 (PRC1) on 2487 promoters (10.2% of the total), for
H3K27me3 on 2206 promoters (9.0%), and for SUZ12
(PRC2) on 1042 promoters (4.3%). A very significant
overlap was observed between promoters bound by
PRC1 and PRC2, which were also tri-methylated on
H3K27, consistent with the fact that PRC1 is dependent
on PRC2-mediated K27 tri-methylation for its ability to
bind to chromatin (Hernandez-Munoz et al. 2005; Pir-
rotta and Gross 2005). Several genes with H3K27me3
enrichments appeared not to have associated CBX8, sug-
gesting that this mark may execute distinct functions
Figure 3. Identification of 43 PcG target genes whose expression changes in Polycomb-depleted cells. (A) Treeview depiction of the
expression changes in Polycomb-depleted cells of 43 direct PcG target genes. (B) XY scatterplot representations of SUZ12, H3K27me3,
and CBX8 enrichments along the gene loci of BMP2, ATF3, BMI-1, and CCND2. The chromosome number and the region covered are
depicted above each panel. (C) Standard ChIP analysis of newly identified Polycomb target genes using the previously identified MYT1
target gene as a positive control. The CCNA2 and HOXA1 genes are presented as negative controls.
Polycomb target genes
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independent of PRC1 complexes. Alternatively, PRC1
might be bound to these genes through the two chromo-
domain-containing CBX8 homologs CBX4 or CBX7. The
large number of genes identified, which were only sig-
nificantly bound by CBX8, are unlikely to be CBX8 spe-
cific targets. In fact, genes belonging to this category,
when subsequently tested in quantitative ChIP analysis,
were found to also possess significant H3K27me3 and
SUZ12 binding, for example, CYP1B1 and DKK2 (cf. Fig.
3C and Supplementary Table 3). Therefore the large
number of genes bound only by CBX8 is likely a conse-
quence of the higher affinity of the CBX8 antibody for its
epitope rather than a reflection of PRC2-independent re-
cruitment. In conclusion, our results using promoter ar-
rays extend the repertoire of PcG target genes to >1000
(Fig. 4A; Supplementary Table 3).
Next we asked: What is the nature of the target genes
identified? Remarkably, we found that the majority of
the genes previously identified or predicted to be PcG
target genes in Drosophila have human homologs iden-
tified as PcG targets in this screen (Fig. 4B; Ringrose and
Paro 2004; Ringrose et al. 2004). In addition to the HOX
genes, we found that Engrailed, Hedgehog, Hairy, and
Caudal all have human PcG target homologs. Interest-
ingly, another target in Drosophila is the Polyhomeotic
locus. As mentioned above, we have found that the hu-
man PcGs also bind to the BMI-1 and CBX8 gene loci,
and now extend this group to include the CBX4 and
CBX7 loci.
PcGs target both stem cell- and differentiation-specific
genes
We wished to study PcG dynamics on target genes in a
biologically relevant model of differentiation. The global
mapping analysis revealed that the PcGs bind many
genes that are specifically induced in various types of
differentiation (Table 1). For example, BMP6 (Kugimiya
et al. 2005), the homebox gene PAX4 (Wang et al. 2004),
MYOG (Rohwedel et al. 1994), DMBT1 (Al-Awqati
2003), and ZIC1 (Sato et al. 2005) are specific differen-
tiation factors induced in osteogenesis, endocrinal differ-
entiation, myogenesis, epithelial cell differentiation, and
neurogenesis, respectively. Recent results have shown
that EZH2 represses the muscle creatine kinase gene
CKM in nondifferentiated myoblasts and is displaced
from the gene promoter upon muscle differentiation,
when the gene becomes activated (Caretti et al. 2004).
Our results show that the PcGs target a large number of
tissue-specific differentiation genes like CKM (see Table
Figure 4. Genome-wide mapping of PcG target pro-
moters. (A) Venn diagram depicts significant overlaps
between the presence of SUZ12, CBX8, and H3K27me3
on promoters. (B) A remarkable conservation of Poly-
comb target genes through evolution from Drosophila
to humans. Several confirmed or predicted Drosophila
PcG target genes are shown in the left column. In our
analysis we have identified their human homologs as
being human PcG targets (see Supplementary Table 3).
(C) A selection of PcG target genes identified in this
study, focusing on those known to be involved in key
pathways controlling development, differentiation,
stem cell biology, and cell fate decisions.
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Table 1. Examples of differentiation genes identified by PcG ChIP-on-chip
Antibodies used
Gene name Function HA CBX8 SUZ12 K27me3
DLX5 Neuronal differentiation + + +
HEY2 Neuronal differentiation + + +
LHX1 Neuronal differentiation + + +
MASS1 Neuronal differentiation + + +
NEFL Neuronal differentiation + + +
NEUROD1 Neuronal differentiation + + +
NEUROG1 Neuronal differentiation + + +
NEUROG2 Neuronal differentiation + + +
NMU Neuronal differentiation + + +
NXPH2 Neuronal differentiation + + +
OLIG2 Neuronal differentiation + + +
PAX3 Neuronal differentiation + + +
PHOX2A Neuronal differentiation + + +
PHOX2B Neuronal differentiation + + +
POMC Neuronal differentiation + + +
POU4F2 Neuronal differentiation + + +
ROBO3 Neuronal differentiation + + +
SEMA5B Neuronal differentiation + + +
SIM1 Neuronal differentiation + + +
TBR1 Neuronal differentiation + + +
ZIC1 Neuronal differentiation + + +
BMP3 Bone differentiation +
TNFSF11 Bone differentiation + +
CHRDL2 Bone differentiation + + +
BMP6 Bone differentiation +
GDF2 Bone differentiation + +
BMP7 Sex differentiation + +
JAG2 Sex differentiation +
DMRT1 Sex differentiation + + +
DMRT2 Sex differentiation + + +
DMRT3 Sex differentiation + + +
SRY Sex differentiation +
DMRTA1 Sex differentiation + +
BMP8B Sex differentiation + +
FGF9 Sex differentiation +
CD4 T-cell differentiation +
MDFI Chondrogenic differentiation + + +
CSRP3 Muscle development +
MYOG Muscle development + +
SYNE1 Muscle development +
CKM Muscle development + +
MYH11 Muscle development + + +
ACHE Muscle development + + +
TNNT1 Muscle development + + +
HAND2 Cardiogenesis +
DLL1 Cell fate/Notch pathway +
DLL3 Cell fate/Notch pathway + + +
NOTCH4 Cell fate/Notch pathway + +
PAX4 Endocrine differentiation + + +
EDAR Epidermal cell differentiation + +
DMBT1 Epithelial cell differentiation + +
THPO Hematopoiesis + + +
KIT Hematopoiesis + + +
LIF Hematopoiesis +
KDR Hematopoiesis + +
TAL1 Hematopoiesis + + + +
BMP4 Mesoderm cell fate decisions +
SHH Mesoderm cell fate decisions + + +
A selection of enriched target genes identified in the ChIP-on-chip analysis using a 24,275 tiled promoter array.
Polycomb target genes
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1), suggesting that the displacement of PcGs from differ-
entiation-specific genes during terminal differentiation
is a general phenomenon (depicted in Fig. 5A, panel i).
To test this, we chose to focus on neuronal differen-
tiation for several reasons. A large number of neuronal
differentiation genes are bound by PcGs (Table 1). The
PcGs are required for neuronal development and self-
renewal of neural stem cells (Leung et al. 2004; Molofsky
et al. 2004). Additionally, there are several well-estab-
lished model systems for neuronal differentiation pro-
cesses. As a model system, we chose the human em-
bryonic teratocarcinoma cell line NT2/D1, which has
neural progenitor cell properties and irreversibly differ-
entiates along a neural lineage upon treatment with reti-
noic acid (RA) (Lee and Andrews 1986).
We selected four genes based on their proposed role in
neuronal differentiation: the gene for the zinc-finger do-
main transcription factor ZIC1 required for normal neu-
ronal differentiation (Grinberg and Millen 2005); the ho-
meobox-containing transcription factor MEIS2; the RA
receptor , RARB; and the gene for neurofilament light
chain, NEFL (Zhu et al. 1997). The expression of these
genes is induced during differentiation (Zhu et al. 1997;
Niederreither et al. 2000) and during RA-induced differ-
entiation of NT2/D1 cells (Fig. 5B; data not shown). Con-
sistent with the increased expression of these genes dur-
ing differentiation, we observed a progressive decrease in
PcG binding and H3K27me3 enrichments on these genes
(Fig. 5B; data not shown). These data are consistent with
the model depicted in Figure 5A, panel i, and since the
PcGs associate with a large number of tissue-specific
genes in differentiated cells, this suggests that the differ-
entiation specific signals, which activate tissue-specific
genes, lead to the displacement of PcGs from the genes.
Subsequently we decided to investigate PcG target
genes, which become silenced during differentiation. A
potential model for how this would occur is depicted in
Figure 5A, panel ii, in which we speculate that PcGs
would be recruited during differentiation. To test this
hypothesis, we selected three genes that are highly ex-
pressed in neuronal progenitor cells but silenced during
differentiation (Fig. 5C). These included genes for the
basic helix–loop–helix (bHLH) proneural transcription
factors OLIG2 (Lee et al. 2005) and NEUROG2 (Ma et al.
1996), and the gene for metallothionein 1G, MT1G. ChIP
experiments showed, in contrast to our expectations, a
strong and significant binding of PcGs together with the
presence of H3K27me3 on the promoters of these genes
in undifferentiated cells (Fig. 5C), with only slight in-
creases during differentiation. These results demonstrate
that binding of PcGs to target genes in undifferentiated
cells does not strictly correlate with transcriptional si-
lencing.
To understand if this intriguing result could be ex-
tended to other genes, we analyzed the binding of the
PcGs to the HOXA locus before and after differentiation
of the NT2/D1 cells. Previous data have shown that the
HOX genes display faithful regulation patterns following
RA-induced differentiation of NT2/D1 cells (Simeone et
al. 1990; Houldsworth et al. 2002). As depicted in Figure
6A and shown in Figure 6B, the (posterior) 5-end genes
(HOXA7–13) are expressed in undifferentiated cells but
are dramatically repressed upon RA treatment. In con-
trast, the genes at the (anterior) 3 end of the locus
(HOXA1–5) become strongly activated. We determined
the binding of EZH2 and CBX8 together with H3K27me3
enrichments on the complete HOXA locus both before
and after induction to differentiate. Consistent with the
genes analyzed in Figure 5, the PcGs are displaced from
the activated HOXA1–5 gene loci during differentiation,
while they are already bound to the HOXA7–13 genes in
undifferentiated NT2/D1 cells (Fig. 6C) and remain
bound throughout the differentiation process and subse-
quent decrease in mRNA expression. These results on
the HOXA cluster expand the set of genes, which are
transcriptionally active in undifferentiated cells yet
bound by PcGs prior to their repression in differentiated
cells.
Discussion
By genome-wide location analysis, we have identified
>1000 putative genes bound by PcG proteins. Strikingly,
these genes contain the key members of the Wnt, TGF,
FGF, Notch, and Hedgehog signaling pathways known to
be the regulators of developmental and differentiation
processes. In addition, target genes are conserved
throughout evolution from Drosophila to human, sug-
gesting that this transcriptional regulatory network is
essential for the development and differentiation of all
multicellular organisms.
Polycomb target genes
By performing gene expression profiling of human em-
bryonic fibroblasts in combination with ChIP-on-chip
experiments, we identified 43 PcG target genes whose
expression is dependent on the PcGs. The large majority
of these genes become derepressed as a result of specific
depletion by siRNAs of the PRC2 components (EZH2,
EED, and SUZ12) or the PRC1 component BMI-1 (39 of
43). These target genes include several known markers of
bone, cartilage, and fat differentiation (Supplementary
Table 2). To put this into context, fibroblasts are prolif-
erating cells of the mesoderm that compose part of the
connective tissue in almost every tissue and organ. They
are derived from mesenchymal stem cells, which are
multipotent precursors, capable of differentiating into
osteoblasts, adipocytes, chrondrocytes, endothelial cells,
and also non-mesoderm-type lineages, such as neuronal-
like cells (Kassem 2004). Interestingly, evidence exists
that embryonic fibroblasts in tissue culture maintain at
least some of the multipotency of mesenchymal stem
cells. For example, mouse embryonic fibroblasts can un-
dergo chrondrogenic and adipocytic differentiation (Ge
et al. 2002; Lengner et al. 2004). Consistent with this, we
found that several markers of osteocytic, chrondrocytic,
adipocytic, and neural differentiation are up-regulated in
Polycomb-depleted cells (Fig. 3A; Supplementary Table
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Figure 5. PcGs bind to genes that are repressed or induced during neuronal differentiation. (A) Models for how PcGs could regulate
gene expression during terminal differentiation. (B) qPCR and ChIP analysis of two PcG target genes (ZIC1 and MEIS2) induced during
neuronal differentiation of NT2/D1 cells treated with 1 µM RA. (C) qPCR and ChIP analysis of two genes (NEUROG2 and OLIG2)
repressed during neuronal differentiation of NT2/D1 cells treated with 1 µM RA.
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2). For example, both the bone morphogenic protein
BMP2 and the Wnt/-catenin signaling protein DKK2
function in terminal osteoblast differentiation (Li et al.
2005). While HEY1 and TCF7 are transcriptionally acti-
vated during osteogenesis (de Jong et al. 2004), both
CHST11 (Kluppel et al. 2005) and PRKG2 (Chikuda et al.
2004) are associated with chrondrocytic differentiation,
the latter being a molecular switch from proliferation to
hypertrophic differentiation of chondrocytes. The G0S2
protein is involved in adipocyte differentiation (Zandber-
gen et al. 2005), and UCP1 is a specific marker of Brown
adipose tissue. In addition, several other target genes are
known regulators of development such as RARB, WT1,
and the homeobox genes SALL1 and HOXA5. In sum-
mary, the combination of ChIP-on-chip and expression
array analysis in human embryonic fibroblasts has iden-
tified 43 novel PcG target genes with important regula-
tory roles in mesenchymal differentiation and develop-
ment.
Strikingly, the expression of only a relatively small
number of the >1000 identified PcG target genes was
affected by depleting PcGs in human embryonic fibro-
blasts, and >90% of the identified target genes are not
detectably expressed. This is consistent with previous
observations by Kirmizis et al. (2004) in SW480 colon
cancer cells depleted of SUZ12. We hypothesize that the
majority of the 1000 PcG target genes identified here in
fibroblasts are permanently silenced. This permanent re-
pression could be due to secondary epigenetic modifica-
tions of the target promoters by, for example, the EZH2
complex itself or by DNA methylation. Supporting this
notion is the demonstration that EZH2 possesses H1K26
methylation activity (Kuzmichev et al. 2004), and since
H1K26me3 can tether HP1 to chromatin (Daujat et al.
2005), this could add an additional layer of transcrip-
tional repression on PcG target genes. Additionally, the
expression of EZH2 has recently been shown to be suf-
ficient for the recruitment of DNA methyl transferases
Figure 6. Polycombs are present on active HOX genes in nondifferentiated cells. (A) Schematic depiction of the gene expression
changes along the HOXA locus upon RA-mediated induction of neuronal differentiation. (B) Quantification of mRNA expression
changes of HOXA genes during neuronal differentiation of NT2/D1 cells by qPCR. (C) ChIP analysis of EZH2, H3K27me3, and CBX8
binding to the promoters of the HOXA1 to HOXA13 genes both before and after 10 d of RA treatment. (D) Displacement of PcGs from
target genes activated during differentiation, for example, ZIC1, MEIS2, RARB, and HOXA1–5 in neuronal differentiation and CKM
in myoblast differentiation. (E) Polycomb “preprogramming” of certain target genes in undifferentiated cells, for example, NEUROG2,
OLIG2, and HOXA9–13. These genes are paradoxically expressed while being bound by PcGs in undifferentiated cells. Several
hypothetical mechanisms for the triggering of PcG repressive function during differentiation are possible, include post-translational
modifications of the PcGs, addition of H1K26me3 or ubiquitinated H2A-K119 marks, recruitment of DNA methyltransferases, the
binding of additional transcriptional repressors, or a combination of these mechanisms.
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to cellular promoters leading to their DNA methylation
and repression (Vire et al. 2005). It is possible that such
secondary repressive modifications are not alleviated in
PcG-depleted cells. As an alternative and complemen-
tary explanation for the lack of expression of a large
number of PcG target genes in fibroblasts, we suggest
that the fibroblasts may lack the specific transcriptional
activators required for the expression of the tissue-spe-
cific target genes such as those listed in Table 1.
Polycomb target genes and cancer
The identification of PcG target genes may also provide
vital mechanistic insights into the precise nature by
which PcGs contribute to cancer. It has been proposed
that cancer originates from nondifferentiated or stem
cell-like cells, referred to as “cancer stem cells” (Reya et
al. 2001). This idea is supported by the recent observa-
tion that mammary stem cells are enriched in premalig-
nant breast tissue (Shackleton et al. 2006). The identifi-
cation of a large number of PcG target genes required for
differentiation (Table 1) strongly suggests that the onco-
genic potential of genes such as BMI-1 and EZH2 can be
ascribed to their role in stem cell maintenance. Another
insight comes from the fact that a significant proportion
of the identified PcG genes are silenced in cancer by
DNA methylation of their promoter sequences. These
include RARB, CCND2, MT1G, KLF4, IGSF4, WT1,
NPTX1, HOXA5, BMP2, and G0S2 (Evron et al. 2001;
Loeb et al. 2001; Fackler et al. 2003; Fukami et al. 2003;
Hagihara et al. 2004; Zhao et al. 2004; Henrique et al.
2005; Lewis et al. 2005). Significantly, as pointed out
above, EZH2 has recently been shown to act as a plat-
form for DNA methyltransferases on certain EZH2 tar-
get genes (Vire et al. 2005). The PRC2 complex could
therefore contribute to cancer development by specifi-
cally silencing tumor-suppressor genes by DNA methyl-
ation. Consistent with this, we have found an inverse
correlation between the expression levels of the PcGs,
EZH2, SUZ12, and BM1–1, and the target genes MT1G,
HOXA5, and RARB in breast cancer (A.P. Bracken, P.
Cloos, and S. Confalonieri, unpubl.). It will be important
in future investigations to determine if the silencing of
these genes in cancer contributes to the development of
the disease and if PcGs have a causal role in this.
Delineating the mechanisms by which PcGs regulate
cell fate decisions
The identification of genes bound by PcGs has enabled
us to begin to address the mechanisms by which they
repress transcription. Our results, based on a model of
neuronal differentiation, suggest at least two alternative
mechanisms (depicted in Fig. 6D,E). The first model is
exemplified by genes such as ZIC1, MEIS2, and HOXA1–
5, which are bound and repressed by PcGs in undifferen-
tiated cells. Upon induction to differentiate, PRC1 and
PRC2 are displaced from these genes by, as yet, uniden-
tified mechanism(s), leading to their derepression. This
model is consistent with previous results, suggesting a
similar role for the PcGs in muscle and germ cell termi-
nal differentiation processes (Caretti et al. 2004; Chen et
al. 2005) and predicts that this is a general phenomenon.
The alternative model describes when PcG target
genes are down-regulated during differentiation (Fig. 6E).
This model is based on the surprising observation that
the PcGs, in some cases, are bound to their target genes
in undifferentiated cells, despite the gene being actively
expressed. Based on our results for OLIG2, NEUROG2,
and HOXA9–13, we propose that these PcG target genes
are already “preprogrammed” to be repressed upon ap-
propriate cell fate signals. Supporting this hypothesis,
the Paro laboratory demonstrated that the Drosophila
PcG and Trithorax proteins bind to Polycomb-Respon-
sive Elements (PREs) and promoters of HOX genes before
their expression levels are set by the early-acting seg-
mentation factors (Orlando et al. 1998). Further support-
ing such a concept, we observed H3K27me3 and SUZ12
enrichments on the entire HoxA locus in mouse embry-
onic stem cells, resembling the profile observed in un-
differentiated NT/D1 cells (Fig. 6C; Supplementary Fig.
S4; data not shown). This suggests that the transcrip-
tional memory system of the HOX genes and other genes
controlling cell fate are preset or “programmed,” possi-
bly by PcGs in the zygote generated from maternal
mRNA. In this model, specific developmental signals
such as RA concentrations could trigger the PcG-repres-
sive capacity by as yet unidentified mechanisms. This
could involve the post-translational modifications of the
PcG proteins, the modification of other proteins/his-
tones by the PcGs, or the specific recruitment/dissocia-
tion of transcriptional regulators from the PcG target
genes (Fig. 6E). Therefore, we propose that the PRCs
function as “platforms” for channeling repressive signals
during developmental and differentiation processes.
In summary, we predict that PcGs form part of an epi-
genetic blueprint for development and differentiation es-
tablished early in embryogenesis. Future investigations
may hopefully unravel the precise mechanistic contribu-
tions of PcG proteins, modifications such as H1K26me3
and ubiquitinated H2A-K119 and associated proteins,
such as HP1 and DNA methyltransferases, on the >1000
genes identified here during multiple types of cell fate
decisions. An additional challenge for the future will be
to harness this knowledge such that we can dedifferen-
tiate or trans-differentiate cells for therapeutic purposes.
Materials and methods
Tissue culture
The human diploid embryonic lung fibroblast TIG3 cell line and
the embryonic carcinoma cell line NTERA2 (NT2/D1) (Lee and
Andrews 1986) were grown in DMEM supplemented with 10%
(v/v) FCS. To induce differentiation of NT2/D1 cells, asynchro-
nously growing cells were seeded at 30% confluency and were
treated 24 h later with 1 µM ATRA (dissolved in DMSO; Sigma).
Cultures treated continuously with RA were collected at 0, 2, 5,
and 10 d for RNA extraction or harvested for ChIP at 0, 5, and
Polycomb target genes
GENES & DEVELOPMENT 1133
10 d. Cultures were reseeded every 3–4 d and collected no less
than 24 h after reseeding.
Generation of antibodies
Two polyclonal CBX8 (hPc3) antibodies “LAST” and “GALD”
were produced in rabbits using synthetic peptides correspond-
ing to amino acids 107–129 (KKPGRSPQDLASTSRAREGLRN
MGL) and 295–318 (KKGQGALDPNGTRVRHGSGPPSSGG) of
human CBX8, respectively. These were coupled to Keyhole
Limpet Hemocyanin (KLH) through the N-terminal lysine resi-
dues and injected subcutaneously into rabbits according to
standard procedures (DAKO). Positive sera produced were affin-
ity-purified on the respective peptide antigens according to stan-
dard procedures. For ChIP assays, 5 µg of a pool of both affinity-
purified antibodies was used per immunoprecipitation.
siRNA interference
Specific siRNA oligos targeting EZH2, EED, SUZ12, and BMI-1
mRNAs were described previously (Bracken et al. 2003; Pasini
et al. 2004b). Cells were transfected using Oligofectamine (In-
vitrogen) and harvested 44 h after transfection.
Quantification of mRNA levels by qPCR
cDNA was generated by RT–PCR using the PE Applied Biosys-
tems TaqMan Reverse Transcription Reagents. Reactions were
determined using the SYBR Green I detection chemistry system
(Applied Biosystems), using an ABI Prism 7300 Sequence De-
tection System. Ubiquitin was used as a control gene for nor-
malization. The sequences of the primers used are available
upon request.
Affymetrix expression analysis
Total RNA was extracted from mock, EZH2, EED, SUZ12, and
BMI-1 siRNA-transfected cells. For each treatment, RNA was
prepared from six independent experiments and was pooled into
one sample to reduce the experimental variation. Targets for
microarray hybridization were synthesized accordingly to the
supplier’s instructions (Affymetrix). The human GeneChip ar-
ray U133A (Affymetrix), which interrogates ∼33,000 transcripts,
was used for gene expression profiling. Fifteen GeneChip arrays
U133A were used for this analysis; for each different condition,
three separate arrays were hybridized with pooled cRNA. Hy-
bridization, washing, staining, scanning, and data analysis were
performed at The Affymetrix Microarray Unit at the IFOM-IEO
campus, Milan, Italy, according to the manufacturer’s instruc-
tions. Expression levels were analyzed using Microarray Analy-
sis Suite (MAS) 5.0 statistical algorithm software (Affymetrix),
using the default parameters and scaling (TGT Value) signal
intensities for all the GeneChip arrrays to a value of 500. The
mock siRNA treatment was used as a baseline condition for
comparison with the polycomb siRNA-treated samples.
ChIP assays
ChIPs were performed and analyzed essentially as described pre-
viously (Bracken et al. 2003). The antibodies used were rabbit
anti-E2F3 (sc-878; Santa Cruz), anti-PolII (sc-899; Santa Cruz),
anti-H3K27me3 (Upstate), anti-SUZ12 (Upstate), anti-HA (sc-
805; Santa Cruz), a mouse monoclonal specific for EZH2 (AC22)
(Pasini et al. 2004b), and an equal mix of the polyclonal anti-
bodies for CBX8, described above. For normal chromatin IPs, the
immunoprecipitated DNA was quantified by real-time qPCR.
The sequences of the PCR primers are available upon request.
Instead for the ChIP-chip analysis, the immunoprecipitated
DNA was amplified by LMPCR as described previously (Ren et
al. 2000) and hybridized to tiled arrays manufactured by
NimbleGen Systems, Inc. (http://www.nimblegen.com).
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